World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 8 June 2015
Main ID:  NCT00724672
Date of registration: 25/07/2008
Prospective Registration: Yes
Primary sponsor: Merck Sharp & Dohme Corp.
Public title: A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)
Scientific title: Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Rheumatoid Arthritis During Different Forms of Anti-Tumor Necrosis-Alpha Treatments.
Date of first enrolment: September 2008
Target sample size: 0
Recruitment status: Withdrawn
Study type:  Observational
Study design:  Time Perspective: Prospective  
Phase:  N/A
Countries of recruitment
Key inclusion & exclusion criteria

Inclusion Criteria:

- Must have active RA (DAS28 >5.1)

- Must have x-ray evidence of an erosive disease,

- Must be eligible for but have never received any anti-TNF treatment,

- Must fulfill the 1987 criteria of the American College of Rheumatology classification
criteria for a diagnosis of RA, for at least 3 months,

- Must have failed standard therapy (methotrexate or leflunomide).

Exclusion Criteria:

- Must not be a women who is pregnant or breastfeeding,

- Must not have a history of any malignancy,

- Must not have an active infection,

- Must not be prone to infection,

- Must not have tuberculosis, hepatitis B, hepatitis C, or HIV,

- Must not have septic arthritis of a native prosthetic joint within the last 12

- Must not have NYHA grade 3 or 4 heart failure,

- Must not have a history of demyelinating disease or systemic lupus erythematosis.

Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
Drug: adalimumab
Drug: etanercept
Drug: infliximab
Primary Outcome(s)
Gene expression (under- or overexpression) in the peripheral blood mononuclear cells [Time Frame: Weeks 0, 4, and 14.]
Secondary Outcome(s)
Disease Activity measured by DAS28 [Time Frame: Weeks 0 and 14]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history